Alembic Pharmaceuticals gains on getting EIR from USFDA for API - I, API - II facility at Panelav
Alembic Pharmaceuticals is currently trading at Rs. 959.60, up by 13.80 points or 1.46% from its previous closing of Rs. 945.80 on the BSE.
The scrip opened at Rs. 958.80 and has touched a high and low of Rs. 971.90 and Rs. 948.00 respectively. So far 3689 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1296.15 on 09-Oct-2024 and a 52 week low of Rs. 725.60 on 03-Mar-2025.
Last one week high and low of the scrip stood at Rs. 971.90 and Rs. 927.80 respectively. The current market cap of the company is Rs. 18870.06 crore.
The promoters holding in the company stood at 69.67%, while Institutions and Non-Institutions held 20.42% and 9.90% respectively.
Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) for the inspection carried out by US Food and Drug Administration (USFDA) at the company's API - I & API - II facility located at Panelav. The inspection was conducted from May 26, 2025 to May 31, 2025.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
